Zsolt Horváth

Dr. Zsolt Horváth

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in The Lancet
Verified
Journal Article
Closed access
JBJosé Baselga
José Baselga
IBIan Bradbury
Ian Bradbury
HEHolger Eidtmann
Holger Eidtmann
SCSerena Di Cosimo
Serena Di Cosimo
EAEvandro de Azambuja
Evandro de Azambuja
MPMartine Piccart-Gebhart
Martine Piccart-Gebhart

1 October 2017 in The Lancet Oncology
Verified
Journal Article
Open access
NBNicholas Butowski
Nicholas Butowski
DTDavid D Tran
David D Tran
LRLawrence D Recht
Lawrence D Recht
MLMichael Lim
Michael Lim
HHHal Hirte
Hal Hirte
SNShona Nag
Shona Nag
Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or not the addition of rindopepimut to standard chemotherapy is able to improve survival in patients with EGFRvIII-positive glioblastoma. In this randomised, double-blind, phase 3 trial, we recruited patients aged 18 years and older with glioblastoma from 165 hospitals in 22 countries. Eligible patients had newly diagnosed glioblastoma confirmed to express EGFRvIII by central analysis, and had undergone maximal surgical resection and completion of standard chemoradiation without progression. Patients were stratified by European Organisation for Research and Treatment of Cancer recursive partitioning analysis class, MGMT promoter methylation, and geographical region, and randomly assigned (1:1) with a prespecified randomisation sequence (block size of four) to receive rindopepimut (500 μg admixed with 150 μg GM-CSF) or control (100 μg keyhole limpet haemocyanin) via monthly intradermal injection until progression or intolerance, concurrent with standard oral temozolomide (150-200 mg/m2 for 5 of 28 days) for 6-12 cycles or longer. Patients, investigators, and the trial funder were masked to treatment allocation. The primary endpoint was overall survival in patients with minimal residual disease (MRD; enhancing tumour <2 cm2 post-chemoradiation by central review), analysed by modified intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01480479. Between April 12, 2012, and Dec 15, 2014, 745 patients were enrolled (405 with MRD, 338 with significant residual disease [SRD], and two unevaluable) and randomly assigned to rindopepimut and temozolomide (n=371) or control and temozolomide (n=374). The study was terminated for futility after a preplanned interim analysis. At final analysis, there was no significant difference in overall survival for patients with MRD: median overall survival was 20·1 months (95% CI 18·5-22·1) in the rindopepimut group versus 20·0 months (18·1-21·9) in the control group (HR 1·01, 95% CI 0·79-1·30; p=0·93). The most common grade 3-4 adverse events for all 369 treated patients in the rindopepimut group versus 372 treated patients in the control group were: thrombocytopenia (32 [9%] vs 23 [6%]), fatigue (six [2%] vs 19 [5%]), brain oedema (eight [2%] vs 11 [3%]), seizure (nine [2%] vs eight [2%]), and headache (six [2%] vs ten [3%]). Serious adverse events included seizure (18 [5%] vs 22 [6%]) and brain oedema (seven [2%] vs 12 [3%]). 16 deaths in the study were caused by adverse events (nine [4%] in the rindopepimut group and seven [3%] in the control group), of which one-a pulmonary embolism in a 64-year-old male patient after 11 months of treatment-was assessed as potentially related to rindopepimut. Rindopepimut did not increase survival in patients with newly diagnosed glioblastoma. Combination approaches potentially including rindopepimut might be required to show efficacy of immunotherapy in glioblastoma. Celldex Therapeutics, Inc.

1 January 2017 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
GRGabor Rubovszky
Gabor Rubovszky
ZHZsolt Horváth
Zsolt Horváth
Rubovszky G, et al. J Breast Cancer. 2017 Jun;20(2):119-131. https://doi.org/10.4048/jbc.2017.20.2.119

1 October 2005 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
EHErika Hitre
Erika Hitre
BBBarna Budai
Barna Budai
VAVilmos Adleff
Vilmos Adleff
FCFerenc Czeglédi
Ferenc Czeglédi
ZHZsolt Horváth
Zsolt Horváth
JKJudit Kralovánszky
Judit Kralovánszky
The present study aimed to prospectively investigate the influence of thymidylate synthase (TS) polymorphisms (5′-TSER, 3′-TSUTR) on the disease-free survival (DFS) and overall survival (OS) of patients with colorectal cancer (CRC) who were treated with adjuvant 5-fluorouracil (5-FU) therapy. Patients were followed up for 19±14 months (median±SD). TS genotypes were determined from the peripheral blood mononuclear cells of 166 patients by polymerase chain reaction–polyacrylamide gel electrophoresis and restriction fragment length polymorphism methods. 5′-TSER 3R homozygotes showed significantly longer DFS (P=0.048) and OS (P=0.009). The 5′-TSER and 3′-TSUTR genotype combination groups showed a significant difference for DFS (P=0.039) and OS (P=0.029). Significantly better DFS (P=0.049) and OS (P=0.043) were observed for 6 bp/6 bp genotypes in 5′-TSER heterozygotes (n=80). Based on this, and on hazard ratios obtained by Cox regression analysis of the DFS of genotype–combinations, the patients were classified as belonging to prognostic groups A and B. The DFS and OS of these two groups showed a highly significant difference (P=0.002 and 0.001). In the multivariate Cox regression model, beside tumour location, the prognostic classification (groups A and B) proved to be an independent prognostic factor. Our data suggest that those TS genotypes and their combinations (group A: 3R/3R with any 3′-TSUTR genotype and 2R/3R with 6 bp/6 bp), which have been reported earlier as having high TS expression, predict significantly longer DFS and OS. We found that a combination of germline TS polymorphisms is an independent prognostic marker in selecting CRC patients with worse prognosis, and it may be worthwhile to examine whether these patients would benefit from an alternative therapy.

1 September 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
BAB. Ataseven
B. Ataseven
HAH.A. Azim
H.A. Azim
NAN. Al-Sakaff
N. Al-Sakaff
SLS. Lauer
S. Lauer
MSM. Shing
M. Shing
TTTran Van Thuan
Tran Van Thuan

1 December 2013 in European Journal of Cancer
Verified
Journal Article
Closed access
GRGabor Rubovszky
Gabor Rubovszky
ILI. Láng
I. Láng
EGE. Ganofszky
E. Ganofszky
ZHZsolt Horváth
Zsolt Horváth
ÉJÉ. Juhos
É. Juhos
EHE. Hitre
E. Hitre